Irinotecan liposome II combination therapy regimen
2024-549-02
Phase 1 small_molecule active
Quick answer
Irinotecan liposome II combination therapy regimen for Non-Muscle Invasive Bladder Urothelial Carcinoma is a Phase 1 program (small_molecule) at Chongqing Claruvis Pharmaceutical Co., with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Chongqing Claruvis Pharmaceutical Co.,
- Indication
- Non-Muscle Invasive Bladder Urothelial Carcinoma
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active